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In the past three decades, molecular tumour profiling and functional studies have led to the identification and validation of crucial genes and pathways that are dysregulated or mutated in specific tumour types. In parallel, a continuously increasing toolbox of rationally targeted drugs has been developed to block some of these cancer drivers with high efficacy. In biomarkerguided early clinical trials, several targeted drugs showed unparalleled activity and became the gold standard of care for patients with the matching molecular tumour profile 1 . Examples of successfully targeted cancer drivers include ERBB2 overexpression in breast cancer, BRAF mutations in melanoma, ABL1 rearrangements in chronic myeloid leukaemia (CML), KIT mutations in gastrointestinal stroma tumours (GISTs), and anaplastic lymphoma kinase (ALK) rearrangements or epidermal growth the comprehensive analysis of cancer genomes across different tumour entities 1 . This revealed that similar cancer driver mutations initially discovered in a single tumour entity are also present in tumours of other anatomical sites. For example, oncogenic BRAF mutations occur in 100% of hairy cell leukaemias, ~50% of melanomas, ~50% of papillary thyroid cancers, ~10% of brain tumours, ~10% of colorectal cancers (CRCs) and with lower frequency in a range of other cancer types 10, 11 . Because cancer drivers are shared between different tumour types, it has been proposed that the traditional classifications of cancers based on the tissue or organ of origin should be replaced by new classifications according to the molecular phenotype, based on molecular alterations shared by tumours across different tissue types [12] [13] [14] . These alterations might represent common targetable vulnerabilities irrespective of the cell or tissue of origin. This led to the idea of extrapolating and generalizing the use of targeted drugs across anatomically distinct cancer types after initial proof of efficacy in one tumour type. Consequently, oncologists are increasingly using molecularly targeted drugs off-label, and patients are included in so-called basket or umbrella trials, which enrol patients with anatomically different cancer types that share a specific molecular alteration that is thought to be responsive to a particular drug [15] [16] [17] [18] [19] [20] . A prominent example of an umbrella trial is the recently launched National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) study, which will examine tumour biopsy specimens from as many as 5,000 patients to identify potentially druggable targets. This trial will provide important insights regarding the feasibility and effectiveness of such novel clinical trial designs 21, 22 . Such trials are an important step towards both identifying subgroups of patients that respond to molecularly targeted therapies and discovering associated biomarkers of response, as well as elucidating mechanisms of primary treatment resistance 19, 23 . In addition, such trials will generate a rich resource needed to direct future basic and translational cancer research to generate data-driven factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) [2] [3] [4] [5] [6] [7] [8] [9] . These examples clearly demonstrate the feasibility and power of biomarker-driven precision medicine.
Traditionally, treatment decisions in cancer care are made by organ-specific multi-disciplinary tumour boards, in which experts in different disciplines, such as medical oncology, radiation oncology and pathology, review and discuss the medical condition and treatment options of a patient together with experts in the respective cancer entity, for example, abdominal surgical oncology, gastroenterology, gynaecology or urology. Recommendations are based on histology, practical treatment options and evidence-based medicine, in which adequately powered phase III randomized controlled trials (RCTs) provide robust data regarding treatment efficacy and safety. In the past decade, technologies for large-scale genomic profiling rapidly evolved, enabling Abstract | How can we treat cancer more effectively? Traditionally, tumours from the same anatomical site are treated as one tumour entity. This concept has been challenged by recent breakthroughs in cancer genomics and translational research that have enabled molecular tumour profiling. The identification and validation of cancer drivers that are shared between different tumour types, spurred the new paradigm to target driver pathways across anatomical sites by off-label drug use, or within so-called basket or umbrella trials which are designed to test whether molecular alterations in one tumour entity can be extrapolated to all others. However, recent clinical and preclinical studies suggest that there are tissue-and cell type-specific differences in tumorigenesis and the organization of oncogenic signalling pathways. In this Opinion article, we focus on the molecular, cellular, systemic and environmental determinants of organ-specific tumorigenesis and the mechanisms of context-specific oncogenic signalling outputs. Investigation, recognition and in-depth biological understanding of these differences will be vital for the design of next-generation clinical trials and the implementation of molecularly guided cancer therapies in the future.
human cancer models and mechanistically investigate the biological implications of co-occurring and mutually exclusive genetic alterations 19, 23 . However, recent basket trials provide evidence that the response to a molecular alteration-specific anticancer drug often depends on the anatomical cancer type; in addition, off-label use of targeted therapies across different tumour entities may not be superior to standard of care 12, 14, 17, 18 . For example, drugs targeting the same oncogenic BRAF V600E mutation showed unprecedented efficacy in melanoma, NSCLC and hairy cell leukaemia, but failed in BRAF
V600E
-mutated CRC 7, 12, 24 . Therefore, the assumption that a driver mutation behaves similarly across different tumour entities may not be generally valid. In line with this, there is compelling experimental evidence that oncogenic drivers and the organization of oncogenic signalling pathways are tissue specific and are therefore important determinants of treatment response and resistance.
In this Opinion article, we summarize the molecular, cellular and systemic determinants of tissue-specific tumour development. We show that the signalling output of an oncogenic driver can differ substantially between tissue types, and we provide selected examples that exemplify how environmental factors shape the tissue-specific signalling of cancer genes. We discuss the implications of tissue context (which cause hereditary breast and ovarian cancer syndrome), cadherin 1 (CDH1; also known as E-cadherin; which cause hereditary diffuse gastric cancer syndrome), RB1 (which cause retinoblastoma), von Hippel-Lindau tumour suppressor (VHL; which cause von Hippel-Lindau syndrome and a clear cell renal cell cancer (ccRCC) predisposition) and KIT (which cause a GIST predisposition) [27] [28] [29] (FIG. 1) .
These well-known examples demonstrate that tissues differ substantially in their susceptibility to specific oncogenic events and that barriers to tumour formation are highly tissue specific. However, alterations in other genes, such as TP53 germline mutations, which cause Li-Fraumeni syndrome, are associated with a much broader spectrum of cancer types. Such genes are therefore considered as general cancer genes. In line with this, a wide variety of sporadic tumours display a predominance of distinct cancer genes based on their site of origin, whereas TP53 mutations are present in many different cancer types (FIG. 2) . For example, VHL is inactivated in sporadic ccRCC, whereas it is only rarely mutated in other tumour entities 30 . Other examples are BCR-ABL1 translocations in CML, APC mutations in CRC and mutations in the tumour suppressor gene RB1 in small cell lung cancer (SCLC) [31] [32] [33] . These examples of tissue-specific genetic events raise the for the design of molecularly targeted therapies and advocate the importance of studying the biology and targeting of cancer in a multi dimensional way. It is our opinion that therapy should take various aspects into account, including the organ type, environmental context and genetic confounders, such as co-occurring mutations. Because our understanding of tissue-specific oncogenic signalling is still in its infancy, we stress the need to investigate the biology of each potential cancer driver in its tissue context. This has the potential to inform and guide clinical trial design, and ensure that the right patients are enrolled in the right basket. Combining the molecular tumour profile with the tissue type will increase treatment efficacy and pave the way towards molecularly precise therapies.
Tissue-specific tumorigenesis Different cell and tissue types show profound differences in their response to oncogenic driver mutations 25, 26 . Such differences are most obvious in hereditary cancer predisposition syndromes such as familial adenomatous polyposis (FAP) caused by adenomatous polyposis coli (APC) germline mutations 27, 28 . Affected people have a nearly 100% lifetime risk of developing CRC, whereas other tumour types are rare. Similar associations exist for other germline mutations, such as those affecting BRCA1 and BRCA2 Figure 1 | Hereditary cancer predisposition syndromes and tissuespecific tumorigenesis. Gene defects underlying hereditary cancer predisposition syndromes, such as alterations in adenomatous polyposis coli (APC), cadherin 1 (CDH1; also known as E-cadherin), BRCA1, von Hippel-Lindau tumour suppressor (VHL) and ataxia telangiectasia mutated (ATM), are associated with a high risk of developing tissue-specific cancer types. By contrast, other gene defects, such as those in DNA mismatch repair (MMR) genes (mutL homologue 1 (MLH1), mutS homologue 2 ( MSH2), MSH6, PMS1
and PMS2) or TP53, are associated with cancers from many different tissues of origin. For each syndrome, associated cancer entities with an at least fourfold increased risk are indicated. ACC, adrenal cortical carcinoma; BC, breast cancer; ccRCC, clear cell renal cell carcinoma; CRC, colorectal cancer; EC, endometrial cancer; FAP, familial adenomatous polyposis; GB, glioblastoma; GC, gastric cancer; HNPCC, hereditary nonpolyposis colon cancer; LE, leukaemia; LY, lymphoid malignancies; OC, ovarian cancer; OS, osteosarcoma; PC, pheochromocytoma (adrenal gland tumour); STS, soft-tissue sarcoma. EGFR  TP53  KRAS  FAT4  STK11  KMT2C  FAT1  CDKN2A  SMARCA4   36%  36%  17%  11%  10%  10%  9%  8%  8%   KRAS  TP53  SMAD4  CDKN2A  ARID1A  KMT2C  GNAS  ATM  PIK3CA   69%  44%  15%  14%  4%  4%  3%  3%  2%   APC  TP53  KRAS  FAT4  PIK3CA  KMT2C  BRAF  SMAD4  ATM   48%  45%  34%  20%  13%  12%  11%  11%  11%   VHL  PBRM1  BAP1  SETD2  KDM5C  MTOR  TP53  PTEN  PIK3CA   43%  30%  11%  10%  6%  6%  5%  3%  3%   Breast cancer  Melanoma  Gastric cancer  Ovarian cancer  PIK3CA  TP53  GATA3  CDH1  KMT2C  ESR1  NCOR1  PTEN  ARID1A   27%  24%  11%  10%  9%  7%  4%  4%  4%   BRAF  GRIN2A  FAT4  CDKN2A  TERT  NRAS  NF1  TP53  ERBB4   45%  20%  20%  19%  18%  17%  16%  14%  13%   TP53  PIK3CA  KRAS  ARID1A  CTNNB1  SMARCA4  BRCA1  ATR  BRCA2   48%  11%  11%  9%  7%  6%  5%  5%  4%   TP53  FAT4  ARID1A  CDH1  KMT2C  PIK3CA  KMT2D  TRRAP  RNF43   34%  18%  14%  13%  11%  10%  10%  9%  9%   T-ALL  Hepatocellular  carcinoma   Prostate cancer  Diffuse large  B cell lymphoma   CDKN2A  NOTCH1  PHF6  FBXW7  DNM2  TP53  PTEN  JAK3  WT1   44%  41%  30%  16%  15%  15%  14%  112%  11%   TP53  TERT  CTNNB1  AXIN1  ARID1A  CDKN2A  KMT2C  PIK3CA  TSC2   28%  21%  19%  8%  7%  6%  4%  3%  3%   KMT2D  BCL2  TP53  CREBBP  MYD88  EZH2  SOCS1  PIM1  TNFAIP3   27%  23%  19%  17%  15%  13%  12%  12%  9%   TP53  PTEN  SPOP  KRAS  FOXA1  KMT2C  EGFR  CTNNB1  PIK3CA   11%  8%  7%  4%  4%  4%  3%  3%  2% question about the underlying molecular and cellular mechanisms that allow or prevent cancer development at different anatomical locations. The most obvious reason for tissue-specific cancer development could be that expression of the cancer driver is limited to the tissue in which the tumour develops. However, most cancer genes are expressed in a wide variety of tissues and are not restricted to tissues from which the cancer originates 26, 34 . This suggests the presence and combinatorial action of other factors, such as the tissue-specific oncogenic function of a cancer driver and the characteristics of the cell of origin (for example, stress responses, connectivity of signalling pathways, signalling output and compensatory mechanisms), as well as pre-existing or gene 35, 36 (FIG. 3) . Several cancer drivers have context-specific effects on stem and progenitor cell self-renewal, maintenance and lineage commitment (FIG. 3a) . For example, APC is a critical regulator of the WNT signalling pathway, which is essential for intestinal stem cell homeostasis 37 . Ablation of WNT signalling in mice results in a complete loss of intestinal epithelial cells 38 , whereas constitutive WNT activation in intestinal stem cells by Apc deletion leads to stem cell-driven intestinal tumorigenesis 39 . By contrast, Apc inactivation fails to transform differentiated intestinal epithelial cells 39 .
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Other cancer drivers generate divergent phenotypes in different cell types within a tissue (FIG. 3b) . For example, the PIK3CA gene (which encodes PI3K catalytic subunit-α) is one of the most frequently acquired genetic and epigenetic changes 25 . In addition, the tissue specificity of individual cancer drivers may be affected by cell-extrinsic factors such as cell-cell signalling, mosaicism, and cooperation and competition between distinct cell types in the context of the respective tumour microand macroenvironments, as well as other environmental factors. Below, we discuss examples of potential molecular and cellular mechanisms that determine which cancer genes are selected during tumour evolution in specific tissue types.
Cell of origin, cellular plasticity and transdifferentiation. The cell of origin and its differentiation status are important determinants of its susceptibility to oncogenic transformation by a cancer 40, 41 . Multiple differentiated cell types also give rise to Kras G12D -induced NSCLC, and the cell of origin influences the NSCLC spectrum and its histopathological phenotype 42, 43 . origin may require a unique set of distinct mutations to be able to serve as the cell of origin of a tumour subtype 44 . Cellular plasticity is crucially involved in tissue-specific tumour development at distinct anatomical sites, such as the pancreas and the skin 35, [45] [46] [47] [48] (FIG. 3d) .
Acinar-to-ductal metaplasia (ADM), a first step towards pancreatic ductal adenocarcinoma (PDAC) development, is characterized by the transdifferentiation of pancreatic acinar cells, which are reprogrammed by oncogenic KRAS to a
The concept that cancer drivers can have distinct functions in different cell types or at different stages of differentiation has been validated impressively in an unbiased forward-genetics transposon-based mutagenesis screen in the lymphoid differentiation lineage 36 (FIG. 3c) . Although transposon mobilization induced T cell acute lymphoblastic leukaemia (T-ALL) in all cases, there was a remarkable difference in the genes that were activated or inactivated in the different cell types 36 . These data support the idea that a particular cell of of tumour development in some tumour types, such as pancreatic ductal adenocarcinoma (PDAC). In this case, a specific oncogenic lesion induces the transdifferentiation of acinar cells in the pancreas to cells with a ductlike phenotype and leads to tumorigenesis, which depends on the continuous expression of the oncogenic lesion. e | Only differentiated cells in a specific tissue type, but not those in most other tissue types, are susceptible to transformation by a particular cancer driver, such as von HippelLindau tumour suppressor (VHL) gene mutations in proximal renal tubular epithelial cells, which give rise to clear cell renal cell carcinoma (ccRCC). f | Cells in other tissue types require the right combination of specific molecular alterations to serve as cells of origin of a tumour, such as TP53 and BRCA mutations in serous ovarian cancers that originate from the distal fallopian tube. g | The same driver lesion induces different tumour types with distinct molecular and phenotypic features, depending on the tissue in which the oncogene is expressed, such as oncogenic BRAF mutations in melanoma, papillary thyroid cancer, hairy cell leukaemia and non-small cell lung cancer (NSCLC).
duct-like phenotype 35, 46, 47 . The reactivation of embryonic signalling pathways, such as Hedgehog and Notch signalling, contributes to cellular plasticity and tumorigenesis 47 . Just as cancer drivers can have context-specific effects in a differentiation lineage, so they can have varying effects in different tissues (FIG. 3e, g ). In basal-cell cancer, inducible expression of a constitutively active smoothened (SMO) mutant protein in the adult mouse epidermis reprogrammed differentiated epidermal cells into embryonic hair follicle progenitor-like cells and induced cancer formation 45 . By contrast, the same SMO mutant was not able to induce ADM or tumour development in the pancreas 49 ( FIG. 3e) . Further to this, the same driver can induce tumours with distinct phenotypes in different tissues (FIG. 3g) . These examples support two important conclusions. First, distinct oncogenic drivers are necessary to induce cellular reprogramming and tumour development at specific anatomical sites. Second, reprogramming occurs only in a specific permissive cellular context, explaining the tissue tropism of certain oncogenes and tumour suppressors.
Tumour suppressor barriers. Tumour suppressor barriers are tissue and context specific and depend on a variety of interacting signalling molecules [50] [51] [52] . Such signalling networks were demonstrated to have important roles during tumorigenesis, because they trigger tumour suppressor barriers in response to oncogenic stress. For example, PTEN is a negative regulator of the PI3K pathway and a tumour suppressor that is deleted in several cancer types, such as prostate cancer 53 . By contrast, ablation of Pten in mice suppresses pre-B cell acute lymphoblastic leukaemia (pre-B-ALL) development owing to activation of AKT and the tumour suppressor p53 (REF. 54 ). During normal B cell development, immature B cells bind to auto-antigens (self-antigens) through their B cell receptor (BCR), leading to autoreactive BCR signalling and B cell elimination (negative selection) 55 . In pre-B-ALL cells, the absence of PTEN causes strong PI3K-AKT signals, which mimic the negative selection of autoreactive B cells and induce tumour cell death via AKT-mediated activation of the p53 cell cycle checkpoint 54 . This context is lost in more mature B cell lymphomas, as strong BCR signals in mature B cells lead to proliferation, not elimination 56 . Tissue-specific effects have also been described for classical oncogenes, such as mutated RAS family members. Oncogenic show no such enrichment in TFBS mutations 65 . In adult stem cells of the colon, which are the cells of origin of CRC, contextspecific mutation signatures correspond to spontaneous deamination of methylated cytosine residues into thymine at CpG sites, which are strongly associated with replication timing and might reflect the high division rate of colonic stem cells 67 . Because many point mutations in CRC driver genes, such as APC, CTNNB1 (encoding β-catenin), TP53 and SMAD4, are similarly C/G to T/A transitions at CpG dinucleotides 67 , deamination-induced C-to-T mutagenesis might be a relevant tissue-specific cancer driver and determinant of point mutation load in this tumour entity. Consequently, chromatin and epigenomic features of the cell of origin are the best predictors of local somatic mutation densities in a cancer cell, and the cell of origin of a cancer can be determined according to the distribution of mutations along its genome 62 . The molecular basis of cell type-specific mutations in different RAS family proteins has been uncovered using mouse genetics. KRAS, HRAS and NRAS mutations occur at varying frequencies across different tumour types in humans 68 (FIG. 2) . KRAS is the signature mutation in NSCLC, whereas HRAS mutations are common in skin cancer 68 . Using an elegant knock-in strategy to express wild-type HRAS from the endogenous Kras locus in mice, it was shown that Hras codon 61 mutations occurred in NSCLC only in the Hras knock-in allele expressed from the Kras locus, but never in the endogenous Hras locus 69 . These data show that the tissue-specific mechanisms underlying Kras mutations in NSCLC and Hras mutations in skin cancer involve tissue-specific gene-regulatory elements rather than differences in the function of the encoded proteins.
Super-enhancers are another possible determinant of tissue-specific tumorigenesis. They are clusters of regulatory elements that control the transcription of genes and have been implicated in cell identity [70] [71] [72] . Super-enhancers are bound and controlled by cell type-specific master transcription factors, such as transcriptional effectors of the WNT, transforming growth factor-β (TGFβ) and leukaemia inhibitory factor (LIF) signalling pathways, which are therefore key drivers of cell state and cell type-specific biology 73 . Cancer cells can acquire super-enhancers at oncogenic drivers through mutation, focal amplification, chromosomal translocation or overexpression of an oncogenic transcription KRAS-induced cancer development occurs only in specific mouse tissues, such as the lung and the pancreas, whereas most other tissue types resist oncogenic transformation [57] [58] [59] [60] . Importantly, these findings are also reflected in the respective human cancer types (FIG. 2) . Mechanistically, KRAS induces distinct tumour-suppressive pathways that contribute to its context-specific oncogenic potency. As an example, in mice, oncogenic KRAS triggers the tumour-suppressive p19 ARF pathway extensively in mesenchymal tissues, such as the musculature, but not in epithelial cells of the lung 60 . Thereby, KRAS-induced p19 ARF expression prevents the formation of muscle-derived sarcomas in mice 60 . In line with this, specific deletion of p19 ARF (which is encoded together with p16
INK4A
by the cyclin-dependent kinase inhibitor 2a (Cdkn2a) gene) in mice induces a shift of the KRAS-induced tumour spectrum towards sarcomas 60 . Mechanistically, cell type-specific epigenetic gene regulation of the Cdkn2a locus and, thus, context-specific expression of its gene products p19 ARF and p16
, is the critical determinant of this tissue-specific cellular response. Polycomb group proteins repress p19 ARF expression in the lung, whereas the SWI/SNF chromatin-remodelling complex member SNF5 (also known as SMARCB1) creates a permissive environment for KRAS-induced p19 ARF expression in mesenchymal tissues 60 . This supports the idea that distinct tumour suppressor barriers or signalling thresholds are operative in different tissue types, even in the presence of the same initial oncogenic lesion.
Chromatin organization, replication timing and regulatory elements. Next-generation cancer genome sequencing and functional assays revealed that the rate of somatic mutations varies considerably across the genomes of different cell types owing to context-specific differences in chromatin organization, DNA accessibility, replication timing and transcription initiation [61] [62] [63] [64] [65] [66] . These effects contribute to the quantitatively and qualitatively different mutation burden of different tumour types. For example, nucleotide excision repair (NER) activity is impaired at active transcription factor-binding sites (TFBSs). This leads to an increased rate of context-specific DNA mutations in active gene promoter regions of distinct tumours, such as melanoma and lung cancer, that depend on NER for the repair of, for example, ultraviolet (UV) light-or smoke-induced DNA lesions, respectively 64, 65 . In contrast to this, cancers that do not rely heavily on NER, such as CRC, factor or an epigenetic regulator that controls enhancer activity 71, 72, 74 . These processes are highly tissue and context specific, generating tumour type-specific super-enhancers, which drive cancer development and progression 75 . For example, in T-ALL, a small monoallelic insertion that creates a binding site for the haematopoietic transcription factor MYB nucleates the formation of a novel contextspecific oncogenic super-enhancer upstream of the oncogene T cell acute lymphocytic leukaemia 1 (TAL1), thereby driving its aberrant expression 76 . In addition, a polymorphism within a super-enhancer element in the first intron of LIM domain only 1 (LMO1) specifically influences neuroblastoma susceptibility and oncogenic addiction to LMO1 through direct modulation of LMO1 expression 77 . This super-enhancer is not present in cancer cells from other non-neuroblastoma tumour types, such as T-ALL, despite the expression of LMO1 in these cells. These examples demonstrate that the cell type specificity of super-enhancers is widely preserved in cancer and contributes significantly to context-specific tumour formation.
The genetic road to cancer. Genomesequencing studies have identified various classes of complex genomic rearrangements, such as chromothripsis, chromoanasynthesis and chromoplexy, that each seem to derive from a single catastrophic event [78] [79] [80] [81] . Thus, genomes can acquire multiple complex aberrations by a single event rather than by sequential multistep carcinogenesis. The frequency of such catastrophic events varies substantially between different tumour entities, ranging from 0% in head and neck cancer and 1.3% in multiple myeloma, to 32% in oesophageal adenocarcinoma and 38% in glioblastoma 82, 83 . Some tumour subtypes, such as sonic hedgehog (SHH)-driven medulloblastoma with mutant TP53, always display chromothripsis 83 . Chromothripsis can be triggered by various mechanisms, for example, high-energy ionizing radiation, double-strand breaks (DSBs) generated by exogenous agents and/or toxins or replicative stress, aborted apoptosis, or chromosomes trapped within a micronucleus, all of which result in defective DNA replication 83, 84 . Such complex rearrangements of chromosomes can cause gene fusions, the disruption of tumour suppressors and the amplification of oncogenes 85 . It is reasonable to assume that differences in the genetic road to cancer have context-specific implications on tumour-driving pathways protects them from reactive oxygen species (ROS)-induced cell death 93 . By contrast, other tissue types, which do not respond to oestrogen, cannot tolerate BRCA1 deficiency. Considering that BRCA1 mutations promote tumour formation almost exclusively in hormone-responsive tissues such as breast and ovary 27, 28 , the link between oestrogens and the survival of BRCA1-deficient cells provides important mechanistic insights into the tissue tropism of BRCA1-deficient cancers.
Oncogenic signalling in context
In addition to the tissue-specific oncogenic function of cancer genes described above, the context-specific organization of oncogenic signalling pathways adds another layer of complexity, which is poorly understood but has important therapeutic implications. Below, we discuss selected examples that exemplify some of the molecular and cellular mechanisms that shape oncogenic signalling pathways in the tissue context.
Context-specific organization of oncogenic pathways. Cellular responses and cell fate decisions are controlled by a limited number of signal transduction pathways. These pathways not only transmit but also encode, process and integrate external and internal signals 94 . Thereby, they fine-tune the level of signal propagation and the output strength, providing a specific and appropriate response to external stimuli 95 . Recently, it has become evident that distinct signalling thresholds exist within a cell, which result in diverse and sometimes opposite cellular responses 52, 95, 96 . The efficacy of drugs targeting distinct cancer driver pathways varies significantly between different cancer entities 7, 12, 24 . Experimental evidence in genetically engineered mouse models (GEMMs) suggests that this is due to tissue-specific signalling outputs (FIG. 4) . For example, different downstream pathways are engaged by oncogenic KRAS in mouse models of PDAC and NSCLC: signalling via 3-phosphoinositide-dependent protein kinase 1 (PDK1) is essential for PDAC development, whereas CRAF is crucial for NSCLC formation 59, 97, 98 . Importantly, amplification of a signal to a certain level (that is, the signalling threshold) seems to be necessary to induce cancer. This threshold differs with tissue type, cell differentiation stage and stage of tumorigenesis, and is often mediated by context-specific engagement of protein kinases and their downstream effector pathways 99 .
as well as on therapeutic responses and the development of therapy resistance 83, 86 . Indeed, chromothripsis has been associated with poor prognosis in melanoma, neuroblastoma and multiple myeloma 83 . However, whether chromothripsis is indeed a catastrophic single event that drives tumorigenesis and differs substantially from the multistep process of carcinogenesis remains to be proved experimentally. Another example that demonstrates that distinct roads to cancer may have important therapeutic implications are hypermutated cancers exhibiting microsatellite instability (MSI). They are significantly associated with the mismatch repair (MMR) gene-deficient CRC subtype (see below) and may be particularly sensitive to immunotherapeutic strategies 87 .
DNA damage and repair, and tolerance of oncogenic stress. DNA repair pathways are significantly associated with distinct cancer types 88 . For example, CRC has the highest number of DNA MMR gene defects 26, 88 . MMR seems to be an important mechanism to prevent the accumulation of mutations during DNA replication in intestinal stem cells, and CRCs arise from rapidly dividing stem cells. By contrast, breast and lung cancers have the highest proportion of altered DSB repair (DSBR) genes 26, 88 . Oestrogen and tobacco smoke can induce DNA DSBs under certain conditions, selecting for the accumulation of DSBR gene defects in breast and lung cancer, respectively 26 . Hormones such as oestrogen have an essential role in maintaining cellular identity and can also drive the proliferation of tissues that express the cognate receptor 89 . Oestrogen exposure is an important risk factor for breast cancer development; oestrogen receptors (ERs) are overexpressed in around 70% of breast cancers, and blockade of ERα activity greatly reduces breast cancer risk 89 . Thus, oestrogens are clearly drivers of the development of ERα-expressing breast cancer. Mechanistically, oestrogeninduced DNA DSBs can be mediated by DNA topoisomerase IIβ (TOP2β), which is recruited together with ERα to the regulatory sites of target genes 90, 91 . In addition, the conversion of oestrogens into genotoxic metabolites is an alternative ERα-independent mechanism for oestrogen-induced DSBs In the pancreas, oncogenic KRAS induces an autocrine feed-forward loop that activates EGFR, which is necessary to amplify the KRAS signalling output to reach a critical threshold necessary for PDAC development [106] [107] [108] [109] (FIG. 4) . In contrast, deletion of Egfr in mouse models of KRAS-driven NSCLC or CRC fails to prevent tumorigenesis 106 . In line with these data, KRAS mutations are predictors of primary resistance towards EGFR inhibition in patients with NSCLC or CRC, but not in patients with PDAC [110] [111] [112] [113] . Indeed, KRAS-driven NSCLC depends on the coordinate input from oncogenic KRAS and insulin-like growth factor 1 receptor (IGF1R), but not from EGFR 105 (FIG. 4) .
These results demonstrate that the cellular output of KRAS signalling is highly tissue specific. When considering therapeutic responses, such findings indicate that treatment efficacy cannot be extrapolated from one KRAS-driven tumour entity to another. For example, treatment of some KRAS-mutant lung and pancreatic tumour models with the MEK inhibitor trametinib uncovered a cell-autonomous fibroblast growth factor receptor 1 (FGFR1)-dependent survival pathway, which is not present in KRAS-mutant CRC cells 114 . Furthermore, depending on the cellular context, FGF signalling can act via autocrine feed-forward loops (that is, in lung cancer), or as a paracrine mediator of stroma-epithelium interactions via secretion of the ligand from the tumour micro environment (that is, in prostate cancer) [115] [116] [117] . The outcome of paracrine FGF signalling is also tissue specific: the pathway drives tumour development in the prostate owing to the paracrine upregulation of androgen receptor signalling and AKT activation [115] [116] [117] , whereas it blocks tumour progression in a patched 1 (Ptch1)-mutant mouse model of medulloblastoma via inhibition of oncogenic SHH signalling 118 . All these findings are supported by recent data showing that receptors often act as cell type-specific mediators and amplifiers of signalling pathways 101 . Thus, different levels
The context-specific preservation of negative feedback provides an explanation for how oncogene addiction maintains a certain level of signalling output, which counteracts intrinsic feedback inhibition 122, 124 . This has significant consequences for the design of molecularly targeted therapies because the blockade of oncoproteins or their downstream effector pathways might have an impact on negative feedback loops and may actually increase the signal output in a tissue-specific manner 24, 125 . For example, in CRC, pharmacological blockade of the BRAF oncogene decreases a negative feedback loop that would otherwise block EGFR signalling. EGFR signalling is subsequently activated, allowing CRC cells to proliferate via an EGFR-induced PI3K-AKT pathway 24 (FIG. 4) . These findings contrast with findings in BRAF-driven melanoma, in which BRAF blockade inhibits MAPK activation of signalling pathway dysregulation and output exist between cancer types of distinct tissue origin, and this affects signalling organization within tumour cells, such as downstream signalling, signalling crosstalk and signalling loops.
Inhibitory crosstalk between different pathways as well as negative feedback loops affecting the same pathway have a central role in health and disease 119, 120 . Such inhibitory signalling circuits fine-tune signalling output under physiological conditions to provide an appropriate response to external stimuli, such as growth factors 95, 96, 119, 121, 122 . Interestingly, the persistence of feedback inhibition is preserved in many cancers and is specific to the tumour cell of origin 122 . However, in other cancers, the downregulation of modulators of these negative feedback programmes, or additional mutational hits that bypass the negative feedback, such as inactivation of phosphatases (such as PTEN), may also occur during tumorigenesis 123 . Figure 4 | Determinants of context-specific oncogenic signalling networks. Schematic overview of RAS-RAF-MEK-ERK-regulated and PI3K−3-phosphoinositide-dependent protein kinase 1 (PDK1)-AKTmTOR-regulated signalling networks in cancer. Receptor tyrosine kinases (RTKs) and RAS, RAF or PI3K oncoproteins signal through both pathways in a context-specific manner to drive cancer initiation, progression and maintenance. As examples of context-specific oncogenic signalling mechanisms, the signalling pathways involved in BRAF-driven colorectal cancer (CRC), KRAS-driven non-small cell lung cancer (NSCLC) and KRAS-driven pancreatic ductal adenocarcinoma (PDAC) development are shown (indicated by coloured triangles). Signalling output is enhanced by the tissue-specific positive-feedback activation of RTKs (for example, epidermal growth factor receptor (EGFR); dashed arrow) or by other RTKs that are engaged by autocrine and paracrine stimuli. Tissue-and cell type-specific negative feedback loops and inhibitory as well as activating cross-signalling exist at various levels. Black arrows represent activating, pro-tumorigenic signalling connections in the canonical signalling pathways, and dashed arrows indicate activating, pro-tumorigenic signalling loops that are regulated by the tissue-specific engagement of RTKs. Inhibitory, antitumorigenic pathways are shown as dashed inhibitory lines. AXL, also known as UFO; FGFR1, fibroblast growth factor receptor 1; IGF1R, insulin-like growth factor 1 receptor; MET, hepatocyte growth factor receptor; PDGFR, platelet-derived growth factor receptor; PKC, protein kinase C; RPS6KA, ribosomal protein S6 kinase-α; SGK, serum-and glucocorticoid-regulated kinase; TF, transcription factor. without affecting EGFR signalling 7, 24 . Therefore, tissue-specific EGFR and PI3K signalling seems to bypass BRAF inhibition and mediate primary treatment resistance in BRAF-driven CRC 24, 126, 127 . Consequently, blocking EGFR or PI3K-AKT signalling together with BRAF inhibition is an effective treatment strategy in preclinical models of CRC 24, 126 . These data show that tumours of distinct tissue origin are driven by complex nonlinear signalling dynamics, even if these tumours result from an identical activating driver mutation, such as BRAF V600E . Taken together, these findings indicate that negative feedback is an important tissue-specific mechanism in cancer, as it is used to fine-tune oncogenic signalling output and thereby increase the fidelity of information transmission. This tight control of pathway activation contributes to a permissive window of context-specific tumorigenesis 25 . For most cancer types and oncogenes, the context-specific signalling loops, in KRAS and PIK3CA in CRC, EGFR amplification and O 6 -methylguanine-DNA methyltransferase (MGMT) methylation in NSCLC, and mutual exclusivity of EGFR amplification and cytosolic isocitrate dehydrogenase 1 (IDH1) or TP53 mutation in glioblastoma 134 . Importantly, these data in part challenge the established concept that genetic alterations impinging on a given molecular pathway tend to be mutually exclusive. Epistasis may account for the tissue-specific accumulation of multiple genetic alterations that act synergistically in a given pathway during tumorigenesis 134, 135 . Examples include amplifications of MAPK3 (also known as ERK1) in KRAS-driven PDAC (synergistic impingement on the MAPK pathway), co-occurring genetic alterations of KRAS, PIK3CA and PTEN in uterine corpus endometrial carcinoma (synergistic impingement on the PI3K signalling pathway) and EGFR mutations and PTEN deletions in glioblastoma (synergistic impingement on the PI3K pathway) (see the cBioPortal for Cancer Genomics). It will be important to test experimentally whether epistatic interactions that act synergistically on a given pathway can be exploited therapeutically by a pathway-focused multiple-targeting approach.
Recent work also provides evidence that tissue-specific differences in oncogenic signalling networks, such as feedback loops or signalling crosstalk, as well as differences in the cellular environment, affect epistatic interactions [133] [134] [135] . In line with this finding, not only are epistatic interactions associated with the cell of origin of a tumour, but they also affect the context-specific biological functions of the epistatically linked genes and the survival of a cancer patient 132 . The cell type specificity of epistatic interactions has important implications for personalized treatment regimens and also affects synthetic-lethal interactions, in which the combination of alterations in two genes leads to cell death, whereas mutation in either gene alone has no effect. The exploitation of synthetic lethality to develop cancer therapies has to consider cell-and tissue-specific epistatic interactions 134 , as it is predicted that synthetic lethality will be efficient only in a subset of tumours carrying the targeted vulnerability 134, 135 . This is consistent with data from large-scale screens and trials showing that synthetic lethality strategies that are efficient in a specific cell or tumour type fail in other types 24, 135 . The order in which alterations in cancer genes occur might also be an important determinant of signalling organization feedback mechanisms and signalling crosstalk of cancer-driving pathways remain largely unknown. Understanding these mechanisms will be vital for the development of more efficient therapies in the future.
The additivity, epistasis and historical contingency of cancer genes. Tissue context-specific relationships between molecular alterations, such as co-occurrence or mutual exclusivity of mutations, have been observed in many cancer types, but in most cases the underlying biological principles and the therapeutic consequences are currently unclear. As described above, KRAS mutations have a different impact on oncogenic signalling organization in distinct tumour types such as CRC, PDAC and NSCLC 59, 98, 106, [128] [129] [130] . The phenotype of these KRAS-driven tumour types is further modified by tissue-specific co-occurring mutations in other cancer genes, such as loss-of-function mutations in serine/ threonine kinase 11 (STK11; also known as LKB1) in NSCLC 131 . The co-occurrence of KRAS and STK11 mutations determines distinct biological features of NSCLC, such as differences in pathway activation and immunogenicity, as well as therapeutic vulnerabilities 131 . Co-occurring mutations may act additively or epistatically during the course of cancer development [132] [133] [134] . They are considered additive when the genes do not interact and their biological consequences are the sum of the single effects. However, additive effects are relatively rare in cancer 132, 134 . Most genes exhibit at least some level of epistatic interaction, having greater or weaker consequences in combination than would be expected from their individual effects 132, [134] [135] [136] . Thereby, epistatic interactions shape signalling pathways in cancer by permitting some and blocking others. The quantification of epistatic interactions in vivo in complex situations such as cancer, which is characterized by dynamically changing environmental conditions, remains a major challenge, and novel approaches to accurately measure such effects are urgently needed.
Using data from more than 3,000 cancers, it has been shown that mutual exclusivity and co-occurrence of cancer drivers is frequent and tissue specific 134 . More than 90% of cancer driver interactions have been detected only in a single tumour type, and at least half of the cancer gene interactions differ in their interaction strength in different tumour types 134 . Examples include context-specific co-occurring oncogenic mutations
Glossary
Chromoanasynthesis
Local gene rearrangements that lead to multiple copy number alterations (including deletions, duplications and triplications) as well as extensive translocations and inversions. These rearrangements result from template switching during locally defective DNA replication.
Chromoplexy
Complex chained DNA rearrangements that affect multiple chromosomes and result from several broken DNA strands.
Chromothripsis
The massive catastrophic shattering and reassembly of one or a few chromosomes, resulting in the simultaneous acquisition of multiple genetic alterations in a cell.
Desmoplasia
A dense fibrous connective tissue reaction, usually to malignant epithelial tumours in the stroma of a carcinoma, caused by the proliferation of fibroblasts and increased deposition of extracellular matrix components.
Mosaicism
The presence of two or more genetically distinct cell populations.
Steatosis
The abnormal retention and accumulation of lipid droplets within cells, resulting in fatty changes in or degeneration of a solid organ.
Super-enhancers
Genomic regulatory regions containing multiple enhancers with a very strong enrichment for transcriptional co-activator binding; these regions therefore drive gene transcription.
Transdifferentiation
A cell fate switch (metaplasia) such that a differentiated adult somatic cell transforms into another mature somatic cell type.
and output, as has been shown in a mouse model of BRAF V600E -driven serrated intestinal cancer 126 . This specific CRC subtype is characterized by a serrated histopathological morphology and progresses through a hyperplasia-serrated adenoma-serrated carcinoma sequence, giving rise to sessile cancers with MSI. In contrast to the classic CRC progression model described by Vogelstein et al. 137 -which is often initiated by APC mutation and subsequent WNT pathway activation, followed by additional genetic alterations, such as RAS pathway and MAPK pathway activation (see the cBioPortal for Cancer Genomics) 138 -BRAF-driven serrated CRC is initiated by an amplification of MAPK signalling, followed by WNT pathway activation during tumour progression 126 . This 'inverted' sequence of MAPK-WNT pathway activation not only has important consequences for oncogenic signalling outputs, such as the specific activation of the p16 INK4A and p19 ARF tumour suppressors in BRAF-driven serrated intestinal carcinogenesis, but might also influence the pathomorphological (serrated histology), genetic (MSI and DNA hypermethylation of CpG islands) and clinical (poor prognosis) characteristics of this CRC subtype 139 . The phenomenon that distinct genetic alterations are beneficial or viable only if other alterations have occurred first, known as historical contingency [140] [141] [142] , differs substantially between different cancer types, such as chronic lymphocytic leukaemia (CLL) and myelodysplastic syndromes (MDS) 143, 144 . For example, in MDS, a genetic 'predestination' exists in which the activation of early cancer drivers, such as genes involved in the RNA splicing machinery, dictate future genetic events and routes of tumour evolution with distinct clinical features and prognostic outcomes 143 . Mechanistically, historical contingency is exemplified by the tissue-specific interplay between genetic alterations in MYC and BCL2 . The anti-apoptotic proto-oncogene BCL-2 is activated by translocation in a variety of B cell lymphomas [147] [148] [149] . MYC hyperactivation induces apoptosis of B lineage cells, but BCL-2 overexpression represents one means of blocking this effect and permitting oncogenic MYC to drive the tumour 147, 150, 151 . In a different tissue type, the epidermis, MYC activation is well tolerated by keratinocytes. In these cells, MYC triggers proliferation, hyperplasia and tumorigenesis, but only very low levels of apoptosis 152, 153 . The presence of paracrine and influence TME heterogeneity 160, 166, [174] [175] [176] [177] [178] . It seems likely that these differences exist, as different types of fibroblast have been identified in the skin and shown to respond differentially to paracrine signals, such as SHH or TGFβ 175, 179 . A context-specific role for TGFβ signalling in stromal fibroblasts has been shown during tumour initiation 180, 181 . Global inactivation of TGFβ receptor 2 (Tgfbr2) in all fibroblasts of the mouse induced tumorigenesis only in the prostate and forestomach 180 . In this case, increased hepatocyte growth factor (HGF) secretion by Tgfbr2-knockout fibroblasts seems to be the underlying mechanism that activates the HGF receptor (MET) in epithelial cells to initiate carcinogenesis specifically in the prostate and forestomach 180 . Therefore, fibroblasts can increase the oncogenic potential of adjacent epithelial cells in specific tissue types. As cancerassociated fibroblasts can secrete high amounts of HGF in human tumours 166 , these findings support the view that the successful outgrowth of transformed cells is dependent not only on their molecular alterations, but also on the advantage that their given microenvironment confers.
Most adult tissues are continuously being renewed from stem cells 165 . Depending on the tissue type, resident stem cells can either receive self-renewal factors from specific cells in their local microenvironment or generate those signals themselves 165 . This might have important consequences for tissue-specific tumorigenesis. In the intestine, mesenchymal cells supply WNT proteins to maintain intestinal stem cells, indicating that in the gut, stem and niche cells are functionally paired 165 . By contrast, epidermal interfollicular stem cells in the skin produce their own WNT ligands, which are required for self-renewal 165 . In agreement with this, the stemness of CRC depends on factors that are secreted from activated myofibroblasts, which overactivate the WNT pathway to drive tumour progression 162 . This suggests that targeting the TME might be an attractive tissue-specific therapeutic option for CRC, for which the treatment strategy would be to switch off the supply of self-renewing factors to cancer cells. Taken together, these data support the idea that TME heterogeneity is an important functional determinant that drives tissue-specific tumorigenesis and represents an attractive target for therapeutic interventions in specific tumour types.
However, there is still a lack of mechanistic understanding of the complex interplay between tumours and their survival signals in the skin might be the determinant of this distinct tissue-specific apoptotic threshold 153 . In human CRC and PDAC, TP53 is commonly inactivated at the transition from high-grade intraepithelial neoplasia to carcinoma, rather than at an earlier stage 137, 154 . This contrasts with breast and liver cancer, in which mutations in TP53 occur early 155 . This observation points to distinct functions of p53 in controlling the invasiveness of tumour cells in CRC and PDAC 126 , and potentially controlling cell cycle arrest in breast cancer 135, 156, 157 . Feedback, signalling crosstalk, environmental factors and complex nonlinear signalling dynamics might dictate the tissue specificity and timing of such sequential processes. These examples illustrate that the exploitation of cancer drivers for improved therapies needs to consider the evolution of the cell type-specific signalling networks that act during tumorigenesis.
Environmental factors
Tissue-specific tumorigenesis and contextspecific oncogenic signalling pathways are also influenced by non-cell-autonomous factors, such as the tumour micro-and macro environment, metabolism, the microbiota, acute and chronic inflammatory processes, infection and immunity, as well as by environmental chemicals and toxins 26, 158 .
The tumour microenvironment. The tumour microenvironment (TME) is an important mediator and modulator of oncogenic signalling pathways [159] [160] [161] [162] , and there are clearly tissue-specific differences in the microenvironment of epithelial cells [163] [164] [165] [166] . One of the best examples of TME heterogeneity is the presence of myofibroblast-like stellate cells specifically in the liver and pancreas 164 . These cells are an important pathogenic driver of tissue fibrosis in both organs 164, 167, 168 . After activation by tissue damage or specific oncogenic insults, stellate cells secrete extracellular matrix (ECM) components, proteases, cytokines and growth factors, which together induce tissue repair but can also promote tumour and desmoplasia formation 164, [167] [168] [169] . Thus, the prominent desmoplastic stroma reaction can distinguish some tumour entities, such as PDAC, from other tumour types, such as sarcomas, even if they are driven by the same oncogene 59, [170] [171] [172] [173] . It remains to be determined whether tissue-specific differences exist in the composition of fibroblast and myofibroblast subtypes and lineages. Such variations might promote or restrain tumour development micro-and macroenvironments and how this interplay affects treatment response and resistance. This is in part due to a lack of appropriate methods to target and analyse specific cell types in vivo. Recent developments in this area include the generation of dual-recombinase-based systems, allowing highly controlled, independent genetic manipulation of specific cell types in whole animals 182, 183 ; such approaches provide a means of investigating the cooperation and competition between different cell populations or subpopulations, and the role of mosaicism in cancer [183] [184] [185] . With the use of such models and other systems 184 , it will also be possible to investigate tissue and cell type-specific cell-cell communication and the contextdependent relationship between gene dose and signalling response, with the aim of determining signalling outputs more quantitatively.
The tumour macroenvironment and metabolism. Obesity, being overweight, and type 1 and type 2 diabetes increase cancer risk and the likelihood of death from specific cancer types, such as colon and pancreatic cancers, suggesting that distinct organ-specific mechanisms are in operation [186] [187] [188] [189] [190] . In a normal pancreas, obesity promotes steatosis, inflammation and fibrosis 189, 191 . In mouse models of PDAC, obesity shapes a specific microenvironment, characterized by the accumulation of hypertrophic adipocytes that secrete high amounts of cytokines, such as interleukin-1β (IL-1β) 189 . This accelerates tumorigenesis and tumour growth, and enhances treatment resistance owing to stellate cell activation, increased desmoplasia, neutrophil infiltration and inflammation, and these effects can be blocked by IL-1β inhibition 189 . This is in contrast to the normal intestine and intestinal tumorigenesis, in which obesity has distinct effects on stem cell function but not obesity-related inflammation 192, 193 . In this tissue, obesity increases the number of intestinal stem cells (via peroxisome proliferator-activated receptor-δ (PPARδ)-mediated WNT activation), reduces the niche dependency of intestinal stem cells and induces non-stem cells to form tumours in mice following Apc loss 193 . Other examples of tissue-specific macroenvironmental cancer drivers are sex hormones, which are involved in cancers of reproductive tissues, such as the breast and prostate 102, 194 . Conditional overexpression of the androgen receptor induces oncogenic transformation of the mouse The response to treatment with immune checkpoint inhibitors such as cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-, programmed cell death protein 1 (PD1)-or PD1 ligand 1 (PDL1)-specific antibodies strongly correlates with mutational load, which is the highest in UV-induced melanomas and smoke-induced NSCLC 81, [210] [211] [212] [213] . In addition, MMR-deficient CRCs exhibiting MSI harbour a hypermutation signature and tend to be sensitive to immune checkpoint inhibitors, as mentioned above. However, there are also examples of tumours that have lower mutation rates and respond well to immunotherapy. In these cases, tissue-specific neoantigens, high PDL1 expression levels or the context-specific immunobiology of the tumour stroma might influence therapeutic efficacy 211, [213] [214] [215] . A recent study revealed that the cytolytic activity of the local immune cell infiltrate in the tumour microenvironment varies substantially across 18 different tumour types 216 . It correlates with specific oncogenic signalling pathways, such as WNT or PI3K, neoantigen load and the presence of exogenous or endogenous viruses, as well as with sensitivity to immunotherapy and overall survival 211, [216] [217] [218] . Taken together, these examples show that the underlying pathogenic mechanisms of tissue-specific tumour development often have important therapeutic implications in the clinic.
The role of the microbiota in tumour initiation and maintenance and its influence on antitumour immunosurveillance is an area of active research 158, 219 . It has been shown that distinct patterns of the intestinal microbiome can drive or restrain the formation of intestinal cancers as well as the treatment response and treatment resistance [219] [220] [221] [222] [223] . In addition, there is an increasing body of evidence that differences in the 'estrobolome' -the aggregate of enteric bacterial proteins that are capable of metabolizing oestrogens -can substantially affect the development of ER-positive breast cancer 224 . Therefore, a role for the microbiome in tissue-specific cancer formation and oncogenic signalling output is an important possibility that remains to be addressed experimentally.
Perspectives
As outlined in this Opinion article, multiple factors and their dynamic interactions determine tumour driver selection and oncogenic signalling organization in a highly tissue-and context-specific manner. This indicates that the therapeutic success of personalized cancer care cannot always be extrapolated from efficacy in other tumour prostate 195 . Moreover, in human prostate cancer specifically, androgen stimulation induces the creation and overexpression of oncogenic ETS fusion genes, which cooperate with PI3K pathway activation to drive cancer progression 102, [196] [197] [198] [199] [200] . Tissue-and context-specific metabolic requirements of cancer cells have been identified recently 201, 202 . Interestingly, tumour metabolism depends on both the genetic lesions and the tissue of origin 202 . Cell type-specific metabolic alterations can make tumour cells selectively dependent on certain nutrients and metabolic pathways, leading to therapeutic vulnerabilities that are specific to the tissue of origin. KRAS-driven NSCLCs incorporate circulating branched-chain amino acids (BCAAs) to satisfy their metabolic requirements. This is in contrast to KRAS-driven PDAC tumours, which have a decreased BCAA uptake. Consequently, interfering with this particular metabolic pathway could provide a therapeutic opportunity for NSCLC but not PDAC 203 .
In addition, metabolic changes in cancers are likely to influence oncogenic signalling organization and output. Targeting of metabolic pathways for cancer therapy should therefore account for context-specific metabolic changes in different tumour types.
Infection, inflammation, the microbiome and other environmental factors. Chronic infections due to Helicobacter pylori, hepatitis B and C viruses, Epstein-Barr virus or human papillomaviruses (HPVs), as well as chronic inflammatory diseases such as hepatitis, pancreatitis and colitis, have been linked to a greater risk of cancer in the respective infected or inflamed organs (for example, the oropharynx, stomach, colon, anus, cervix, pancreas or liver) 158, 204, 205 . Persistent infections and inflammation drive epithelial cell proliferation 206, 207 . In addition, activated immune cells produce highly reactive molecules containing oxygen and nitrogen, which can damage DNA 207, 208 . Recent work demonstrates that simultaneous DNA damage and cell division during inflammation leads to cancer because dividing cells are more vulnerable to mutations caused by DNA damage 207 .
Other environmental factors such as exposure to UV light or toxins (for example, smoke) can induce an extraordinarily high rate of mutations, resulting in the activation of diverse cancer drivers 209 . Although the developing tumours are subsequently genetically very heterogeneous, they do harbour mutational signatures that are associated with the cancer aetiology 81 . ; patient-derived xenografts (PDXs) and orthotopic, syngenic engraftment models 225, 226, 228 ; and both genetically engineered and carcinogeninduced autochthonous small and large animal models [226] [227] [228] 231 (FIG. 5a) . Each model has its own advantages and disadvantages, depending on the scientific question to be addressed. Cancer modelling in pigs is now a rapidly evolving new field, addressing the unmet need for genetically defined human-scale preclinical cancer models [231] [232] [233] . The characterization and validation of cancer drivers and their epistatic interactions in distinct tissue types is clearly a great have appropriate clinically approved drugs to target all of the various cancer drivers identified so far in patients; and third, we are not able to mechanistically investigate and understand the biology of a molecular alteration in its tissue-specific context in a patient with cancer.
Instead, preclinical model systems are needed that closely reflect the biology of specific molecular subtypes of human cancer [225] [226] [227] [228] [229] [230] . This includes cell-based in vitro models (organoids and spheroids) derived from human, porcine and murine tumours and from normal tissues that have been transformed by distinct cancer drivers 225, 226, 230 ; in vitro 3D cancer models Figure 5 | Approaches to identification, analysis and validation of cancer drivers in context. a | Cross-species comparative characterization of distinct heterogeneous tumour entities improves the signal-to-noise ratio and identifies substantially altered pathways, transcriptional regulators, missense mutations or copy number changes that are likely to drive the tumour and are potential therapeutic targets. The comparison of human cancers with corresponding genetically engineered or carcinogeninduced mouse and pig tumour models serves as a filter to identify shared alterations. Cancer modelling in pigs is a rapidly evolving field that is driven by the need for more humanized tumour models for preclinical studies. Systems biology and data integration are used to define relevant molecular subtypes of a cancer type on the basis of putative driver mutations, cooccurring alterations and druggable targets. Such bioinformatic analyses will help to model these molecular cancer subtypes, for example, by genetic engineering in the mouse germline (to create genetically engineered mouse models (GEMMs)), or by multiplexed somatic gene engineering of an appropriate target cell in vitro (for example, in organoids) or in vivo (generating somatic GEMMs) using CRISPR-Cas9, short hairpin RNAs (shRNAs) or overexpression systems. Thereby, it is possible to reproduce most of the features that are unique for the particular contextspecific tumour subtype. In addition, patient-derived xenografts (PDXs), orthotopic syngenic engraftment models and carcinogen-induced models, which may recapitulate important features of a specific tumour subtype (for example, hypermutation in carcinogen-induced models), can be used. b | These subtype-specific cancer models can then be used to understand the tissue-specific signalling networks that result from the molecular alterations or to identify context-specific targets by retroviral shRNA-based, CRISPR-Cas9-based library, drug or synthetic-lethality screens. These models can also be used to analyse drug resistance or validate therapeutic targets preclinically through the application of inducible shRNA or CRISPR-Cas9 systems, dual-recombinase technology or drug treatment studies. Genetically defined pig cancer models can be used to carry out more representative, molecularly guided, context-specific treatment trials on a human scale. Knowledge gained from this approach can then be exploited to prioritize drugs and treatment trials with stratified patients in the clinic. lncRNA; long non-coding RNA.
challenge in the context of the many genomic aberrations and their frequent co-occurrence in human cancers. Cross-species comparative tumour analyses and computational approaches can be used to define co-occurring genetic alterations and synergistic epistatic interactions, as well as mutual exclusivity, and findings from such studies will help us to model these specific molecular cancer subtypes in a tissue context 134, 226 . A strategy might be to introduce a number of mutations into the appropriate target cell in vitro or in vivo in order to reproduce most of the features that are unique for the particular tumour subtype (FIG. 5a) . This would enable us to answer the question of how individual mutations contribute to the tumour phenotype and how they influence intervention strategies. The advent of CRISPR-Cas9-mediated gene editing enables us, for the first time, to introduce combinatorial genetic alterations into specific somatic cells with high efficacy 230, [234] [235] [236] [237] [238] . Multiplexed somatic CRISPR-Cas9-based genome editing has been shown to be a powerful tool to model relevant human cancer subtypes closely, and with this approach, we have the potential to better understand the context-specific biological basis of cancer drivers in vitro and in vivo 230, [238] [239] [240] [241] [242] . In addition, new ways to genetically validate cancer genes as appropriate therapeutic targets in their specific tissue context and to evaluate primary and secondary therapy resistances have been developed recently (FIG. 5b) . These include short hairpin RNA (shRNA) or dualrecombinase strategies that allow for the inducible inactivation of cancer genes in autochthonous tumours 182, 183, 243, 244 . In addition, dual-recombinase-based sequential genetic manipulation enables the timing and stages of tumorigenesis to be modelled 183 . Cancer subtype-specific shRNA, CRISPR-Cas9 and pharmacological screens are other attractive options for identifying context-specific therapeutic vulnerabilities 245, 246 .
Over the past few decades, the efficacy of treatment regimens established in preclinical cancer models has often not been translated into the clinic, indicating that conventional models are poor predictors of clinical efficacy 228 . This is probably due to the limitations of xenotransplantation models that use established human cancer cell lines and of tumour models that do not adequately recapitulate the matching human tumour subtype. However, the past two decades have seen the development of several next-generation models that faithfully recapitulate human cancer and predict therapeutic responses more accurately than other models 227, 228 . Therefore, we propose that pipelines of well-characterized model systems for relevant cancer subtypes should be established in order to carry out preclinically guided and prioritized clinical trials. This will increase success rates and save costs and resources.
Comprehensive molecular tumour profiling will greatly aid clinical decision-making and improve cancer care. Together with an increasing arsenal of targeted drugs, this information will provide us with the tools to match the right patient to the right drug. Effective sharing and dissemination of patient molecular tumour profiles and response data will be essential to achieving this goal. However, tissue context has to be considered and empirically tested, as it is an important determinant of treatment response and resistance.
We believe that taking both the molecular tumour profile and the anatomical site into account is likely to be a superior approach to considering either of these in isolation for the purposes of predicting the drug response in a patient. Therefore, a thorough understanding of the molecular mechanisms involved in tissue-specific tumour biology and drug responses is needed for the design of novel next-generation targeted treatment regimens.
